Simone Fishburn - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Simone Fishburn's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Simone Fishburn
Verified
Editor-in-Chief, BioCentury
California
Beats
Economics And Economic Policy , Financial And Commodity Markets , Investment
I do not cover hate speech.
Content
By Jeff Cranmer, Simone Fishburn Verified| BioCentury Verified Back to SchoolBioCentury’s editors assess opportunities, challenges for expedited approval pathwayBioCentury’s editors assess the challenges and opportunities for the expedited approval pathway around the world. By Jeff Cranmer, Executive EdITorAug 30, 2021 | 1:10 PM GMTBioCentury’s 2021 Back to School focuses on accelerated approval, the pathway that helps drugs get to patients faster for severe diseases with no alternatives using less data than normal.
By Simone Fishburn Verified| BioCentury Verified Novo Nordisk A/S is developing ties with Japanese universities to find and foster opportunities in immunology. The program's backers want to break new ground, both among researchers not used to commercializing their ideas and in a company not known for academic collaborations. To date, Novo Nordisk has kept relatively quiet about partnering with academics to access innovation - unlike many other pharmas that have placed public-private partnerships front and center in their research strategies.
By Jeff Cranmer, Simone Fishburn Verified| BioCentury Verified Back to SchoolBioCentury’s editors assess opportunities, challenges for expedited approval pathwayBioCentury’s editors assess the challenges and opportunities for the expedited approval pathway around the world. By Jeff Cranmer, Executive EdITorAug 30, 2021 | 1:10 PM GMTBioCentury’s 2021 Back to School focuses on accelerated approval, the pathway that helps drugs get to patients faster for severe diseases with no alternatives using less data than normal.
Company Info
BioCentury
BioCentury Inc. is a biotechnology-focused business intelligence and analytics company based in Redwood City, California. With over 30 years of experience, it specializes in providing strategic insights and data analysis tailored to the biopharma and biotech industries. The company reported a revenue of $16.2 million. BioCentury offers the BCIQ platform, which includes modules for tracking companies, products, and financial data. This platform helps clients identify trends, partnerships, and investment opportunities. Additionally, BioCentury provides analytical content that includes market trend analysis, visual data tools, and expert interviews. The company also facilitates networking through exclusive events and workshops, connecting C-suite executives and investors within the biopharma community.
'+1 650-595-5333
Founded: 1992